Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;113:e152-e155
doi: 10.1161/CIRCULATIONAHA.105.595538
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Armstrong, E. J.
Right arrow Articles by Sabatine, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armstrong, E. J.
Right arrow Articles by Sabatine, M. S.
Related Collections
Right arrow Acute coronary syndromes
Right arrowRelated Article

(Circulation. 2006;113:e152-e155.)
© 2006 American Heart Association, Inc.


Clinician Update

Inflammatory Biomarkers in Acute Coronary Syndromes

Part II: Acute-Phase Reactants and Biomarkers of Endothelial Cell Activation

Ehrin J. Armstrong, MD, MSc; David A. Morrow, MD, MPH; Marc S. Sabatine, MD, MPH

From the Department of Medicine (E.J.A.), Massachusetts General Hospital, and the TIMI Study Group (D.A.M., M.S.S.), Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass.

Correspondence to Marc S. Sabatine, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail msabatine@partners.org


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 


*    Introduction
 
The inflammatory etiology of atherosclerosis has prompted a search for biomarkers of inflammation that predict risk for coronary artery disease and its sequelae. Within the acute coronary syndromes (ACS), inflammatory biomarkers may provide independent information regarding pathophysiology, prognosis, and optimal therapeutic strategies. On the basis of the hypothesis that different pathophysiological processes provide nonoverlapping information regarding risk stratification and disease management, this review series addresses biomarkers for each step in the inflammatory process that leads to ACS. Part I reviewed cytokines; this part reviews acute-phase reactants and biomarkers of endothelial cell activation; subsequent parts will address biomarkers of oxidative stress, angiogenesis, extracellular matrix degradation, and platelet activation.


*    Acute-Phase Reactants
 
In the acute-phase response, cytokines drive production of acute-phase reactants, defined by >25% change in circulating concentration during an inflammatory response. These markers may also remain elevated chronically because of continuing inflammatory stimuli (Table).


View this table:
[in this window]
[in a new window]
 
Inflammatory Biomarkers in ACS

C-Reactive Protein
C-reactive protein (CRP) is a pentraxin acute-phase protein, members of which are evolutionarily conserved in most vertebrates.1 Hepatocytes and possibly smooth muscle cells and macrophages transcriptionally activate production of CRP in response to inflammatory cytokines, including interleukin-1 and interleukin-6.2 CRP is a robust clinical marker because of its stability, reproducible results, and ease of assay.

Although it was originally proposed as a nonspecific marker of inflammation, several reports suggest that CRP may play a direct pathophysiological role in the development and progression of atherosclerosis. Proposed mechanisms include induction of endothelial dysfunction,3 promotion of foam cell formation,4 inhibition of endothelial progenitor cell survival and . . . [Full Text of this Article]


Related Article:

Issue Highlights
Circulation 2006 113: 919. [Extract] [Full Text]



This article has been cited by other articles:


Home page
Evid Based Complement Alternat MedHome page
G. Yang, Z. Fang, Y. Liu, H. Zhang, X. Shi, Q. Ji, Q. Lin, and R. Lin
Protective Effects of Chinese Traditional Medicine Buyang Huanwu Decoction on Myocardial Injury
Evid. Based Complement. Altern. Med., February 8, 2009; (2009) nep013v1.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
F. Cambronero, F. Marin, V. Roldan, D. Hernandez-Romero, M. Valdes, and G. Y.H. Lip
Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis
Eur. Heart J., January 9, 2009; (2009) ehn538v1.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
W Wojakowski, M Kucia, M Kazmierski, M Z Ratajczak, and M Tendera
Circulating progenitor cells in stable coronary heart disease and acute coronary syndromes: relevant reparatory mechanism?
Heart, January 1, 2008; 94(1): 27 - 33.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. C. Becker
Emerging Paradigms, Platforms, and Unifying Themes in Biomarker Science
J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1777 - 1780.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
C. Zoccali, G. Tripepi, and F. Mallamaci
Dissecting Inflammation in ESRD: Do Cytokines and C-Reactive Protein Have a Complementary Prognostic Value for Mortality in Dialysis Patients?
J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S169 - S173.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndromes
J. Am. Coll. Cardiol., July 18, 2006; 48(2): 386 - 395.
[Full Text] [PDF]